Freenome, Inc. has made a significant advancement in cancer detection with the launch of its SimpleScreen Lung test. This innovative test allows for simultaneous screening of lung and colorectal cancer through a single blood draw, marking a notable enhancement in the company’s personalized cancer detection portfolio.
The announcement was made on October 20, 2026, and is expected to have a substantial impact on patient care within the medical laboratory services industry. By combining two independently validated tests, Freenome aims to streamline the screening process for patients, making it more efficient and accessible.
Background
Freenome, Inc. is a company focused on developing advanced medical laboratory services, particularly in cancer detection. It operates under the SIC classification of 8071, which pertains to services in medical laboratories. The company is publicly traded on the Nasdaq under the ticker symbol FRNM. Freenome has been recognized as an emerging growth company, indicating its focus on innovation and expansion within the healthcare sector.
What the Filing Says
According to the recent filing, Freenome's SimpleScreen Lung test was clinically validated in a study involving adults aged 50 to 80 with a significant smoking history. The test demonstrated an impressive 85% sensitivity at 50% specificity and a 99.8% negative predictive value. This means that only about two out of every 1,000 people with a negative result would actually have lung cancer.
Furthermore, the test's performance estimates were adjusted to reflect target distributions of age, sex, lung cancer stage, and histologic subtype, making it a tailored solution for the intended use population.
Impact
The introduction of the SimpleScreen Lung test is expected to affect a wide range of stakeholders, including patients, healthcare providers, and competitors in the medical laboratory services sector. The dual screening capability may enhance patient outcomes by facilitating early detection of cancers, which is crucial for effective treatment.
What's Next
The filing does not specify what happens next following the launch of the SimpleScreen Lung test. However, it is anticipated that Freenome will continue to develop its product offerings and seek further validation and regulatory approvals to enhance its market position.